Compare AbbVie Inc (ABBV) vs Match Group Inc (MTCH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Match Group Inc — how do they compare? AbbVie Inc trades at $252.62 (market cap $449.91B), while Match Group Inc trades at $38.39 (market cap $9.14B). The key difference: AbbVie Inc is far larger — about 49.2× Match Group Inc's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | MTCH | |
|---|---|---|
Market Cap | $449.91B | $9.14B |
Sector | Health | Media |
52-Week High | $261.07 | $39.18 |
52-Week Low | $184.85 | $28.90 |
Enterprise Value | $513.38B | $12.09B |
Dividend Yield | 2.72% | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
MTCH trades at $39.18, up 3.38% in the last session, with a bullish technical signal and consistent earnings beats. The stock shows strong fundamentals with a 73.8% gross margin and 18.83% net income margin, supported by positive cash flow trends. Recent news highlights a turnaround narrative, with Tinder stabilizing and Hinge driving growth.
Outlook is positive with a consensus price target of $41.63, implying 6.3% upside. Risks include high debt levels and user decline concerns. Analysts are bullish (53% buy ratings), but investors should monitor execution on growth initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Match Group Inc
Match Group is a provider of online dating products. The firm became public in 2015 and was more than 80% owned by IAC/InterActiveCorp until IAC spun it off in the second quarter of 2020. The company has a vast portfolio of different online dating service providers, including Tinder, Match.com, OkCupid, Plenty of Fish, and Meetic. Match Group has more than 45 brands of online dating sites and/or apps, from which it generates user fee revenue (95%) and advertising revenue (5%).
Read more on MTCH →
